Aronex Pharmaceuticals, Inc.

Other

Baylor College of Medicine

Genometrix Genomics Incorporated

Massachusetts Institute of Technology

Houston Advanced Research Center

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Research Development Foundation

Triplex Pharmaceutical Corporation

Michael E Hogan

Robert F Rando

Daniel J Ehrlich

Mark Alexander Hollis

Susan Fennewald

Joseph G Zendegui

Kenneth Loren Beattie

Joshua O Ojwang

Rajender S Varma

John Shumaker

Mitchell D Eggers

William J Balch

Barry E Burke

Bernard B Kosicki

Richard Hart Mathews

Dennis D Rathman

R Allen Murphy

Mitch D Eggers

Yves Pommier

Bharat B Aggarwal

Leopoldo G Mendoza

Thomas L Wallace

Chang-Lee Chen

Ganapathi R Revankar

Nilabh Chaudhary

Joshua O Ojwaug

Paul A Cossum

Joshua O Oiwana

Abhijit Mazumder

Takkellapati S Rao

Donald J Kessler

Veeraiah Bodepudi

Krishna Jayaraman

The invention provides devices for preparing a reaction substrate for use as an assay device, and methods of using these devices. The devices prepare reaction substrates comprising arrays of biosites bound to reaction substrates. The devices have a plurality of bundled capillary tubes that convey capture probes from a storage area for eventual deposition onto a biosite on a reaction substrate.

Methods for fabricating an array for use in multiplexed biochemical analysis

A method and compositions for treating viral infection (IV) vitro and in vivo using a guanosine-rich oligonucleotide. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity and integrase inhibition activity.

Guanosine-rich oligonucleotide integrase inhibitors

A method and apparatus for analyzing molecular structures within a sample substance using an array having a plurality of test sites upon which the sample substance is applied. The invention is also directed to a method and apparatus for constructing molecular arrays having a plurality of test sites. The invention allows for definitive high throughput analysis of multiple analytes in complex mixtures of sample substances. A combinatorial analysis process is described that results in the creation of an array of integrated chemical devices. These devices operate in parallel, each unit providing specific sets of data that, when taken as a whole, give a complete answer for a defined experiment. This approach is uniquely capable of rapidly providing a high density of information from limited amounts of sample in a cost-effective manner.

Multiplexed molecular analysis apparatus and method

A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotide. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity and integrase inhibition activity.

Anti-viral guanosine-rich oligonucleotides and method of treating HIV

The invention provides methods for preparing a reaction substrate for use as assay devices comprising parallel printing of arrays of biosites on reaction substrates, wherein each biosite comprises a single type of capture probe bound to the reaction substrate and the array of biosites is deposited on the reaction substrate by a capillary bundle printer device.

Guanosine-rich oligonucleotides having sequences that favor the formation under physiological conditions of a stable four-stranded structure containing two stacked guanosine quartets (G4s) are disclosed. These oligonucleotides demonstrate enhanced nuclease resistance, cellular uptake and biological efficacy. Methods and composition for treating viral infection using these guanosine-rich oligonucleotides are also disclosed. Certain embodiments of the new oligonucleotides are 16-17 nucleotides long and contain at least one C-5 propynyl dU substitution. A method for designing anti-viral oligonucleotides is also disclosed.

Anti-viral guanosine-rich tetrad forming oligonucleotides

The oligonucleotides have sufficient guanosine to form a guanosine tetrad and can be composed of at least about 40% guanosine nucleotides, the nucleotide sequence containing at least two runs of at least two guanosines. Some of the new oligonucleotides also contain phosphorothioate backbones and 3&prime; end modifications. Representative guanosine-rich oligonucleotides of the present invention demonstrate anti-viral activity in tissue culture against HSV-2, HIV-1, HCMV and FMLV, and show specific inhibition of bacterial RNA polymerase enzymes T7 and T3, the FMLV and HIV-1 reverse transcriptase enzyme and eukaryotic RNA polymerase.

Anti-viral guanosine-rich oligonucleotides

A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotides. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. They can be composed of at least about 40% guanosine nucleotides. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity.

A method and apparatus for identifying molecular structures within a sample substance using an array having a plurality of test sites upon which the sample substance is applied. Each test site includes a probe formed therein to bond with an associated target molecular structure. An electrical signal is applied to the test site and the electrical properties of the test sites are detected to determine which probes have bonded to an associated target molecular structure.

Multi-site detection apparatus

A method and apparatus are disclosed for identifying molecular structures within a sample substance using a monolithic array of test sites formed on a substrate upon which the sample substance is applied. Each test site includes probes formed therein to bond with a predetermined target molecular structure or structures. A signal is applied to the test sites and certain electrical, mechanical and/or optical properties of the test sites are detected to determine which probes have bonded to an associated target molecular structure.

Optical and electrical methods and apparatus for molecule detection

Multi site molecule detection method

The present invention provides novel methods of treating anti-neoplastic and non-neoplastic cell proliferative diseases. The present methods involve administration of triplex forming oligonucleotides to humans to inhibit the biological activity of tumor necrosis factor. Also provided are methods of treating neuro-oncologic states and renal cancer.

Uses of triplex forming oligonucleotides for the treatment of human

A nucleic acid transporter to deliver a nucleic acids into cells, comprising a cationic compound having a cationic head group for binding the nucleic acid and a lipid tail for association with the membrane. A cationic compound usually is a polyamine or a short basic peptide. The lipid tail is usually selected from the group consisting of plant steroid, animal steroid, isoprenoid compound, aliphatic lipid, pore forming protein, pore forming peptides and fusogenic peptides. The cationic head and the lipid tail are linked through a carbamate linkage. When polyamine is used, it is preferably either spermidine or spermine and the nucleic acid can be any of a variety, including triplex forming oligonucleotides, antisense oligonucleotide, aptamers, ribozymes, plasmids and DNA for gene therapy. Also described is a method for treating individuals using the transporter linked to a therapeutic nucleic acid.

Amphipathic nucleic acid transporter

Growing community of inventors

The Woodlands, TX, United States of America

Michael E Hogan